Eplerenone, diabetes, and chronic kidney disease in patients hospitalized for acute heart failure: findings from the EARLIER trial

Table 2 Association of diabetes/CKD categories with cardiovascular death and/or hospitalization

	Model 1		Model 2		Model 3		P-for-interaction between diabetes and CKD
	HR (95% CI)	P-value	HR (95% CI)	P-value	HR (95% CI)	P-value	P-for-interaction between diabetes and CKD
No Diabetes & No CKD	(reference)		(reference)		(reference)		0.049
Diabetes & No CKD	0.76 (0.24 to 2.35)	0.63	0.73 (0.24 to 2.28)	0.59	0.67 (0.21 to 2.12)	0.49
No Diabetes & CKD	0.90 (0.40 to 1.99)	0.79	0.91 (0.41 to 2.04)	0.82	0.92 (0.41 to 2.09)	0.84
Diabetes & CKD	2.57 (1.29 to 5.12)	0.007	2.50 (1.25 to 4.98)	0.10	2.33 (1.12 to 4.84)	0.02

HR, hazard ratio; CI, confidence interval
Model 1, unadjusted model
Model 2, adjusted for age and sex
Model 3, adjusted for age, sex, prevalence of hypertension and atrial fibrillation, prior heart failure hospitalization, estimated glomerular filtration rate and b-type natriuretic peptide at baseline
Bold values indicate significant difference

ISSN: 1475-2840